CN115177695B - Traditional Chinese medicine composition for whitening skin and removing freckles and application thereof - Google Patents
Traditional Chinese medicine composition for whitening skin and removing freckles and application thereof Download PDFInfo
- Publication number
- CN115177695B CN115177695B CN202210987357.8A CN202210987357A CN115177695B CN 115177695 B CN115177695 B CN 115177695B CN 202210987357 A CN202210987357 A CN 202210987357A CN 115177695 B CN115177695 B CN 115177695B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- chinese medicine
- traditional chinese
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 48
- 230000002087 whitening effect Effects 0.000 title claims abstract description 46
- 206010014970 Ephelides Diseases 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 203
- 244000307697 Agrimonia eupatoria Species 0.000 claims abstract description 28
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 28
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 28
- 235000020221 chamomile extract Nutrition 0.000 claims abstract description 28
- 229940119217 chamomile extract Drugs 0.000 claims abstract description 28
- 235000000125 common agrimony Nutrition 0.000 claims abstract description 28
- 239000001599 crocus sativus l. flower extract Substances 0.000 claims abstract description 28
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 28
- 229940076591 saffron extract Drugs 0.000 claims abstract description 28
- 241000222336 Ganoderma Species 0.000 claims abstract description 24
- 240000001548 Camellia japonica Species 0.000 claims abstract description 19
- 240000000774 Cunila origanoides Species 0.000 claims abstract description 19
- 235000018274 Cunila origanoides Nutrition 0.000 claims abstract description 19
- 235000014866 Dictamnus albus Nutrition 0.000 claims abstract description 19
- 235000018597 common camellia Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 241001313857 Bletilla striata Species 0.000 claims abstract description 15
- 241000220317 Rosa Species 0.000 claims abstract description 15
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims abstract description 15
- 229940051810 licorice root extract Drugs 0.000 claims abstract description 15
- 235000020725 licorice root extract Nutrition 0.000 claims abstract description 15
- 244000248557 Ophiopogon japonicus Species 0.000 claims description 26
- 239000002537 cosmetic Substances 0.000 claims description 9
- 229930195210 Ophiopogon Natural products 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 45
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 210000002752 melanocyte Anatomy 0.000 abstract description 7
- 230000008591 skin barrier function Effects 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 5
- 240000002948 Ophiopogon intermedius Species 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 44
- 239000011550 stock solution Substances 0.000 description 26
- 241000252212 Danio rerio Species 0.000 description 22
- 210000002257 embryonic structure Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 15
- 230000036564 melanin content Effects 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 210000004204 blood vessel Anatomy 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 206010008570 Chloasma Diseases 0.000 description 8
- 240000009022 Smilax rotundifolia Species 0.000 description 8
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 230000035784 germination Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 102000003425 Tyrosinase Human genes 0.000 description 6
- 108060008724 Tyrosinase Proteins 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 230000034303 cell budding Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 240000008397 Ganoderma lucidum Species 0.000 description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 4
- 229940124200 Melanin inhibitor Drugs 0.000 description 4
- 102000005348 Neuraminidase Human genes 0.000 description 4
- 108010006232 Neuraminidase Proteins 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 230000036244 malformation Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 241000234435 Lilium Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037072 sun protection Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000012045 crude solution Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000258 photobiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for whitening skin and removing freckles, which is prepared from the following raw materials in parts by weight: 8-10 parts of ginseng extract, 8-10 parts of dittany bark extract or bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract, and 2-4 parts of camellia extract or rose extract. The traditional Chinese medicine composition provided by the invention not only acts on melanocytes, but also can inhibit inflammatory reaction, repair skin barrier, whiten and remove spots in multiple dimensions.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines and cosmetics, and particularly relates to a traditional Chinese medicine composition for whitening skin and removing freckles and application thereof.
Background
In recent years, as the aesthetic level of appearance of skin is improved, more eastern women pay more attention to their own complexion. Some loving women have difficulty in having white skin and tender appearance due to the influence of various factors. The dull dry water-deficient skin is caused by a plurality of reasons, such as congenital genetic factors, acquired sub-health factors, disease factors, dietary factors, environmental factors and the like. Particularly for women entering middle-aged and elderly people, various in-vivo and in-vitro problems are accumulated, melanin deposition, melanocyte metabolism disorder and the like are more likely to occur, and a series of skin problems such as freckle, senile plaque, chloasma, skin blackening, dark complexion, wax yellow and the like are presented. Therefore, in China society believing "one hides one hundred chores", the problem of female health whitening is always a beauty problem which is attracting attention.
Many factors affect chloasma or pigmentation, for example: endocrine disorders, local inflammatory reactions, and even barrier damage are all related, so preventing melanogenesis by acting on melanocytes alone does not solve the skin problem of increased melanosis well. Many products are effective on a single principle, such as single inhibition of tyrosinase activity, or single blocking of melanin from running to epidermis, etc., and have slow effect and limited degree of effect.
Most of the prior whitening products are singly acted on melanocytes or melanin products, so that the improvement period of the skin color of consumers is long and the whitening products are easy to repeat.
Disclosure of Invention
In view of the above, the technical problem to be solved by the invention is to provide a traditional Chinese medicine composition for whitening skin and removing freckles and a preparation method thereof.
In a first aspect, the invention provides a traditional Chinese medicine composition for whitening skin and removing freckles, which is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract or bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract, and 2-4 parts of camellia extract or rose extract.
Optionally, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of glabrous greenbrier rhizome extract and 2-4 parts of camellia extract.
Optionally, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of glabrous greenbrier rhizome extract and 2-4 parts of rose extract.
Optionally, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract and 2-4 parts of camellia extract.
Optionally, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of glabrous greenbrier rhizome extract and 2-4 parts of rose extract.
In a second aspect, the invention provides application of the traditional Chinese medicine composition in preparation of cosmetics for whitening skin and removing freckles.
Optionally, the cosmetic comprises one or more of skin cleaning, lotion, cream, essence, isolation, sun protection, and foundation.
Compared with the prior art, the invention provides a traditional Chinese medicine composition for whitening skin and removing freckles, which is prepared from the following raw materials in parts by weight: 8-10 parts of ginseng extract, 8-10 parts of dittany bark extract or bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract, and 2-4 parts of camellia extract or rose extract. The invention has the effects of inhibiting tyrosinase activity, accelerating melanin metabolism and reducing generated melanin through multiple whitening paths. The factors forming melanin and chloasma are also involved in inflammatory reactions and impaired skin barriers, and it is also important to combat inflammation and repair barriers. The traditional Chinese medicine composition provided by the invention not only acts on melanocytes, but also can inhibit inflammatory reaction, repair skin barrier, whiten and remove spots in multiple dimensions.
Drawings
FIG. 1 is a side view of the body surface melanin inhibiting effect of a normal control group, a 1% group, and a 2% group of zebra fish embryos;
FIG. 2 is a bar graph of body surface melanin content of zebra fish embryos of normal control, 1% and 2% groups;
FIG. 3 is a side view of the length and budding amount of the new blood vessels of the zebra fish embryos of the normal control group, the 1% group and the 2% group;
FIG. 4 is a bar graph of the germination rate of zebra fish embryos from the normal control, 1% and 2% groups;
FIG. 5 is a bar graph of the length of the new blood vessels of the zebra fish embryos of the normal control group, the 1% group, and the 2% group.
Detailed Description
The invention provides a traditional Chinese medicine composition for whitening skin and removing freckles, wherein components for resisting inflammation and repairing barriers are added into the traditional Chinese medicine composition, the traditional Chinese medicine composition has good effects on inflammatory pigmentation and skin barrier damage type freckles, and the traditional Chinese medicine whitening and freckles-fading formula which is purely natural and has multiple functions is provided.
The traditional Chinese medicine composition provided by the invention is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract or bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract, and 2-4 parts of camellia extract or rose extract.
In some specific embodiments of the invention, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of glabrous greenbrier rhizome extract and 2-4 parts of camellia extract.
In some specific embodiments of the invention, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of glabrous greenbrier rhizome extract and 2-4 parts of rose extract.
In some specific embodiments of the invention, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract and 2-4 parts of camellia extract.
In some specific embodiments of the invention, the traditional Chinese medicine composition for whitening skin and removing freckles is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of glabrous greenbrier rhizome extract and 2-4 parts of rose extract.
The traditional Chinese medicine composition for whitening skin and removing freckles provided by the invention comprises 8-10 parts of ginseng extract, preferably 8, 8.5, 9, 9.5, 10 or any value between 8 and 10 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles provided by the invention also comprises 8-10 parts of cortex dictamni extract or 8-10 parts of bletilla striata extract, preferably 8, 8.5, 9, 9.5, 10 or any value between 8 and 10 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles provided by the invention also comprises 6-8 parts of chamomile extract, preferably 6, 6.5, 7, 7.5, 8 or any value between 6 and 8 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles also comprises 4-6 parts of lucid ganoderma extract, preferably 4, 4.5, 5, 5.5 and 6 or any value between 4 and 6 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles also comprises 4-6 parts of pseudo-ginseng extract, preferably 4, 4.5, 5, 5.5 and 6 parts or any value between 4 and 6 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles also comprises 4-6 parts of saffron extract, preferably 4, 4.5, 5, 5.5 and 6 or any value between 4 and 6 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles also comprises 4-6 parts of hairyvein agrimony extract, preferably 4, 4.5, 5, 5.5, 6 or any value between 4 and 6 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles also comprises 4-6 parts of ophiopogon root extract, preferably 4, 4.5, 5, 5.5 and 6 or any value between 4 and 6 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles also comprises 2-4 parts of licorice extract, preferably 2, 2.5, 3, 3.5, 4 or any value between 2 and 4 parts.
The traditional Chinese medicine composition for whitening skin and removing freckles provided by the invention also comprises 2-4 parts of camellia extract or 2-4 parts of rose extract, preferably 2, 2.5, 3, 3.5, 4 or any value between 2 and 4 parts.
The invention also provides application of the traditional Chinese medicine composition in preparing cosmetics for whitening skin and removing freckles.
Wherein the cosmetic comprises one or more of skin cleaning, lotion, cream, essence, isolation, sun protection, and foundation.
The invention has the effects of inhibiting tyrosinase activity, accelerating melanin metabolism and reducing generated melanin through multiple whitening paths. The factors forming melanin and chloasma are also involved in inflammatory reactions and impaired skin barriers, and it is also important to combat inflammation and repair barriers. The traditional Chinese medicine composition provided by the invention not only acts on melanocytes, but also can inhibit inflammatory reaction, repair skin barrier, whiten and remove spots in multiple dimensions.
In order to further understand the present invention, the following examples are provided to illustrate the traditional Chinese medicine composition for whitening skin and removing freckle and the application thereof, and the scope of the present invention is not limited by the following examples.
In the following examples, ginseng extract, dittany bark extract, bletilla striata extract, chamomile extract, ganoderma lucidum extract, pseudo-ginseng extract, saffron extract, hairyvein agrimony extract, ophiopogon root extract, licorice root extract, camellia extract, rose extract, ligusticum wallichii extract, polygonum cuspidatum extract and lily extract are all commercially available.
Example 1
9 parts of ginseng extract, 9 parts of dittany bark extract, 7 parts of chamomile extract, 5 parts of lucid ganoderma extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract, 5 parts of hairyvein agrimony extract, 5 parts of dwarf lilyturf tuber extract, 3 parts of licorice root extract and 3 parts of camellia extract. Mixing the traditional Chinese medicine extracts according to a proportion, and dispersing the mixture in 560 parts of water to obtain the traditional Chinese medicine composition stock solution for whitening skin and removing freckles.
Comparative example 1
9 parts of ginseng extract, 9 parts of dittany bark extract, 7 parts of chamomile extract, 5 parts of ganoderma lucidum extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract, 5 parts of hairyvein agrimony extract, 5 parts of dwarf lilyturf tuber extract and 3 parts of camellia extract.
Comparative example 1 based on example 1, the Glycyrrhiza glabra extract was removed, the other conditions being unchanged.
Comparative example 2
9 parts of ginseng extract, 9 parts of dittany bark extract, 7 parts of chamomile extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract and 3 parts of camellia extract.
Comparative example 2 based on example 1, the ganoderma lucidum extract, the agrimony extract, the ophiopogon root extract were removed, and the other conditions were unchanged.
Comparative example 3
9 parts of ginseng extract, 9 parts of dittany bark extract, 7 parts of chamomile extract, 5 parts of szechuan lovage rhizome extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract, 5 parts of giant knotweed extract, 5 parts of lily extract, 3 parts of licorice root extract and 3 parts of camellia extract.
Comparative example 3 based on example 1, the glossy ganoderma extract was replaced with the Ligusticum wallichii extract, the hairyvein agrimony extract was replaced with the Polygonum cuspidatum extract, the radix Ophiopogonis extract was replaced with the Lily extract, and the other conditions were unchanged.
Comparative example 4
5 parts of ginseng extract, 5 parts of dittany bark extract, 3 parts of chamomile extract, 3 parts of lucid ganoderma extract, 3 parts of pseudo-ginseng extract, 3 parts of saffron extract, 3 parts of hairyvein agrimony extract, 3 parts of dwarf lilyturf tuber extract, 3 parts of liquorice root extract and 3 parts of camellia flower extract
Comparative example 4 the parts of ginseng extract, dittany bark extract, chamomile extract, ganoderma lucidum extract, pseudo-ginseng extract, saffron extract, hairyvein agrimony extract and ophiopogon root extract were reduced on the basis of example 1.
Example 2
9 parts of ginseng extract, 9 parts of dittany bark extract, 7 parts of chamomile extract, 5 parts of lucid ganoderma extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract, 5 parts of hairyvein agrimony extract, 5 parts of dwarf lilyturf tuber extract, 3 parts of licorice root extract and 3 parts of rose extract. Mixing the traditional Chinese medicine extracts according to a proportion, and dispersing the mixture in 560 parts of water to obtain the traditional Chinese medicine composition stock solution for whitening skin and removing freckles.
Example 3
9 parts of ginseng extract, 9 parts of bletilla striata extract, 7 parts of chamomile extract, 5 parts of lucid ganoderma extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract, 5 parts of hairyvein agrimony extract, 5 parts of dwarf lilyturf tuber extract, 3 parts of glabrous greenbrier rhizome extract and 3 parts of camellia extract. Mixing the traditional Chinese medicine extracts according to a proportion, and dispersing the mixture in 560 parts of water to obtain the traditional Chinese medicine composition stock solution for whitening skin and removing freckles.
Example 4
9 parts of ginseng extract, 9 parts of bletilla striata extract, 7 parts of chamomile extract, 5 parts of lucid ganoderma extract, 5 parts of pseudo-ginseng extract, 5 parts of saffron extract, 5 parts of hairyvein agrimony extract, 5 parts of dwarf lilyturf tuber extract, 3 parts of glabrous greenbrier rhizome extract and 3 parts of rose extract. Mixing the traditional Chinese medicine extracts according to a proportion, and dispersing the mixture in 560 parts of water to obtain the traditional Chinese medicine composition stock solution for whitening skin and removing freckles.
Test set one
The whitening and microcirculation efficacy of the traditional Chinese medicine composition stock solution prepared in the example 1 is evaluated through zebra fish embryo experiments.
1. Reagents and materials
24-well plates, 5ml centrifuge tubes, plastic pipettes, petri dishes, pipette, glass slides, holt Buffer solution, methylcellulose.
2. Instrument for measuring and controlling the intensity of light
Constant temperature incubator, zebra fish culture system, upright fluorescence microscope, continuous zoom stereoscopic microscope.
3. Test design
3.1 test group
The test was performed in a total of 3 groups, namely, a normal control group, a 2% group and a 1% group, wherein the normal control group was not added with the stock solution of the traditional Chinese medicine composition in the culture dish, the 2% group was added with the stock solution of the traditional Chinese medicine composition diluted to 2% in the culture dish, namely, diluted to 2% based on the stock solution of example 1, and the 1% group was added with the stock solution of the traditional Chinese medicine composition diluted to 1% in the culture dish, namely, diluted to 1% based on the stock solution of example 1.
3.2 packet design
Three auxiliary wells were set for each concentration, with 20 embryos per well.
Table 1 dose design table
4. Test method
4.1 whitening efficacy verification
1) Day0, add 2% and 1% diluted stock solutions of the Chinese medicinal composition to 2% and 1% group petri dishes, respectively.
2) Dayl. The wild zebra fish 24hpf embryos of AB line were collected 180 and added to the petri dish, and the embryos were grouped according to 20 embryos per group, and each group was repeated three times, with a specific grouping scheme being shown in 3.2.
3) Day3, observing the development state of the melanin on the body surface of the embryo, selecting representative 2-3 tails for each group to record photographing, and carrying out quantitative analysis.
4) Day4-Day6, data analysis and processing.
4.2 microcirculation efficacy validation
1) Day0, add 2% and 1% diluted stock solutions of the Chinese medicinal composition to 2% and 1% group petri dishes, respectively.
2) Dayl, collecting 180 embryos of AB-line transgenic zebra fish 24hpf, adding into a culture dish, grouping according to 20 embryos of each group, and repeating each group three times, wherein the specific grouping scheme is shown in 3.2. After grouping, except for the normal control group, 2% and 1% groups were modeled with angiogenesis inhibitors, and zebra fish microcirculation injury models were constructed.
3) Day3, observing the microcirculation development state of the embryo, selecting a representative 2-3 tail for fluorescence microscopic imaging of each group, and carrying out quantitative analysis.
4) Day4-Day6, data analysis and processing.
5. Analysis of results
5.1 whitening efficacy verification
The procedure was followed as shown in 4.1, with deformity rates and mortality rates counted for the 2% and 1% groups after 48 hours, and the melanin content of the normal control group, 2% group and 1% group were compared.
The 2% group zebra fish embryo development is basically normal without obvious malformation, the body surface melanin is reduced compared with the normal control group, the 1% group embryo development is basically normal without obvious malformation, and the body surface melanin is reduced compared with the normal control group.
Referring to fig. 1, fig. 1 is a side view of the melanin inhibiting effect of the body surface of zebra fish embryos of normal control group, 1% group and 2% group. The area of the melanin plaque in the graph was counted. The melanin content of the 1% group is reduced (36+/-10)% compared with that of the normal control group, and the melanin content of the 1% group and the normal control group are obviously different (P < 0.05). The melanin content of the 2% group is reduced (66+/-10)% compared with that of the normal control group, and the melanin content of the 2% group and the melanin content of the normal control group are obviously different (P < 0.01).
Referring to table 2, table 2 shows the melanin contents (average value ± SE) of the normal control group, the 1% group, the 2% group, the normal control group, the melanin content of 1 ± 0.04,1% and the melanin content of 0.64 ± 0.10,2% group, the melanin content of 0.34 ± 0.10,1% group being significantly different from the normal control group (P < 0.05), and the 2% group being significantly different from the normal control group (P < 0.01).
TABLE 2 melanin content (average.+ -. SE) in normal control, 1% and 2% groups
Referring to fig. 2, fig. 2 is a bar graph of the body surface melanin content of zebra fish embryos of normal control group, 1% group, and 2% group. The melanin content of the 1% group is (64+ -10)% (P < 0.05) of the normal control group. The melanin content of the 2% group is (34+ -10)% (P < 0.01) of the normal control group.
5.2 microcirculation efficacy validation
The procedure was performed as shown in 4.2, and after 48 hours the malformation rate and mortality were counted for the 2% and 1% groups, and the length and sprouting rate of the new blood vessels were compared for the normal control group, the 2% group and the 1%.
2% of zebra fish embryos are basically normal in development without obvious deformity, the length and the budding rate of new blood vessels are increased compared with those of a normal control group, 1% of zebra fish embryos are basically normal in development without obvious deformity, and the length and the budding rate of new blood vessels are increased compared with those of the normal control group.
Referring to fig. 3, fig. 3 is a side view of the length and budding amount of zebra fish embryo neovascularization in the normal control group, 1% group, and 2% group.
And counting the sprouting rate of the blood vessels in the graph. The germination rate of the 1% group is increased (88+/-8)% compared with that of the normal control group, and the germination rate are extremely obviously different (P < 0.001). The germination rate of the 2% group is increased (92+/-2)% compared with that of the normal control group, and the germination rate are extremely obviously different (P < 0.001).
TABLE 3 budding rate (average.+ -. SE) of normal control group, 1% of test article, and 2% of test article
The 1% group was very significantly different from the normal control group (P < 0.001), and the 2% group was very significantly different from the normal control group (P < 0.001).
Referring to fig. 4, fig. 4 is a bar graph of the germination rate of zebra fish embryos from the normal control group, the 1% group, and the 2% group. Wherein, the germination rate of 1% group is (188+/-8)% (P < 0.001) of the normal control group. The germination rate of the 2% group is (192+/-2)% of that of the normal control group (P < 0.001).
TABLE 4 length of neovasculature in normal control group, test 1% group, test 2% group (average SE)
The 1% group had very significant differences from the normal control group (P < 0.001), and the 2% group had significant differences from the normal control group (P < 0.05).
Referring to fig. 5, fig. 5 is a bar graph of the length of the new blood vessels of zebra fish embryos of normal control group, 1% group, 2% group. The angiogenesis length of 1% group is (199+ -13)% (P < 0.001) of the normal control group, and the angiogenesis length of 2% group is (186+ -10)% (P < 0.05) of the normal control group.
The results show that, when the traditional Chinese medicine composition stock solution with the concentration diluted to 2% and 1% is added into the culture environment of 24hpf zebra fish embryos until the embryo development is 72hpf,2% of zebra fish embryos are basically normal and have no obvious deformity, the body surface melanin is reduced compared with the normal control group, and the angiogenesis length and the sprouting rate of blood vessels are both increased compared with the normal control group. The embryo development of 1% group is basically normal without obvious malformation, the melanin on the body surface is reduced compared with the normal control group, and the angiogenesis length and the budding rate of blood vessels are both increased compared with the normal control group. In conclusion, the raw liquid of the traditional Chinese medicine composition provided by the invention can effectively inhibit the melanin of the zebra fish embryo and promote capillary angiogenesis of the zebra fish embryo when the concentration is 2% and 1%. Experiments prove that the stock solution of the traditional Chinese medicine composition provided by the invention can effectively inhibit melanin generation, effectively promote capillary angiogenesis and has the potential of improving blood vessel circulation.
Test group II
The therapeutic effect of the stock solution of the traditional Chinese medicine composition on chloasma was systematically evaluated by using the stock solution of the traditional Chinese medicine composition prepared in example 1 on chloasma subjects.
110 subjects with chloasma are selected, skin care is carried out after facial cleaning every day, the traditional Chinese medicine composition stock solution is used for 2 times/d locally, the continuous use is carried out for 28d, and the curative effect observation is carried out after the treatment is finished.
Evaluation criteria:
(1) The inhibition rate of the neuraminidase: 4mL of a buffer solution (phosphoric acid-citric acid mclvains buffer solution) with pH of 6.8 is added to samples of the stock solutions of the traditional Chinese medicine compositions with concentrations of 0.2%, 0.4%, 0.8%, 1.6% and 2.0%, the mixture is preheated in a constant temperature water tank at 37 ℃ for 10 minutes, 4mL of an aqueous solution of the complex aminoacase (0.05 g/L mclvains buffer solution) is added, the mixture is fully stirred, the mixture is reacted at 37 ℃ for 15 minutes, the absorbance (A1) at 475nm is measured, a solution without the stock solution of the traditional Chinese medicine composition is additionally arranged, the absorbance (A2) is measured at 475nm according to the method, a blank control group is finally arranged, and neither the stock solution of the traditional Chinese medicine composition nor the solution of the complex aminoacase is added, and the absorbance (A3) is measured at 475nm according to the method.
The calculation formula of the inhibition rate of the neuraminidase is as follows: inhibition ratio = (A2-A1)/(A2-A3) ×100%
(2) The effective rate is as follows: the following 4 grades are proposed according to the first 2 curative effect evaluation standards in the "clinical diagnosis of chloasma and curative effect determination standard (revised manuscript in 2003)" (established in the skin disease professional committee pigment group of the Chinese and Western medicine combination society, 2013, month 12): (1) basic cure: visually, the area of the color spots subsides by more than 90 percent, and the color is basically disappeared; the index of decrease after treatment is more than or equal to 0.8. (2) The effect is shown: visually, the color spot area subsides by more than 60 percent, and the color is obviously lightened; the index of decrease after treatment is more than or equal to 0.5. (3) The method is effective: visually, the area of the color spots subsided by more than 30%, and the color was faded; the index of decrease after treatment is more than or equal to 0.3. (4) Invalidation: visual inspection, the area of the color spots subsides by less than 30 percent, and the color change is not obvious; the index of decrease after treatment is less than or equal to 0.
The total effective rate calculation formula is: total effective rate = (basic cure + significant effect + effective)/100 x 100%
The inhibition rate of the neuraminidase:
table 5 shows the inhibition ratios of the crude solutions of the Chinese medicinal compositions diluted to 0.2%, 0.4%, 0.8%, 1.6% and 2.0% in concentration.
TABLE 5 inhibition ratio of Chinese medicinal composition stock solutions diluted to different concentrations to the neuraminidase
The effective rate of treatment is as follows:
table 6 shows the effectiveness of treatment of 110 subjects after 28d of the stock solution of the pharmaceutical composition in use.
Table 6 Chinese medicinal composition stock solution treatment effectiveness
Test group III
1 object and method
1.1 subjects 40 female subjects, aged 25-50 years, were selected in Dongguan Huang Gusheng, traditional Chinese medicine hospitals. All subjects had received notification and signed informed consent.
1.2 inclusion criteria
(1) The skin photo-biological type is type II or III, and mainly uses indoor activities, can strictly comply with experimental requirements, and signs volunteer informed consent.
(2) Women aged 25-50 years;
(3) The course of the disease is more than or equal to 1 and less than or equal to 36 months;
(4) Skin patients with facial inflammation, eczema, psoriasis and the like which influence the observation of curative effect;
(5) No history of insolation prior to treatment;
(6) No treatment was received within 28d prior to participation in the subject study;
1.3 exclusion criteria
(1) Male patients;
(2) Patients older than 25 years old and older than 50 years old;
(3) Pregnant or lactating women:
(4) Patients with severe endocrine disease;
(5) Has serious primary diseases of cardiovascular, renal, hepatic, hematopoietic systems and the like;
(6) There are breast enlargement, mass and proliferative diseases;
(7) Patients with active infectious diseases;
(8) Patients with mental illness and severe neurosis can not cooperate with the therapeutic person.
1.4 method
40 subjects were selected and after facial cleansing in the morning and evening, the whole face was continuously used for 28 days with 2 times/d of the stock solution of the Chinese medicinal composition prepared in example 1.
1.5 evaluation of efficacy
Subjective evaluation of the subjects: after 28d, subjective evaluation was performed, and the content included in the subjective evaluation content included improvement in 4 aspects of clear, level, mottle, and acne marks. The evaluation criteria are classified into three classes of significant improvement, some improvement, and no improvement.
1.6, in the process of product safety evaluation and re-diagnosis, adverse reaction evaluation is carried out on the subjects, and the subjects are inquired whether the faces of the subjects have symptoms such as erythema, tingling and the like, if the symptoms appear, the correlation between the test products and the test products is evaluated through a patch test.
1.7 statistical analysis the above indicators were analyzed using SPSS19.0 software, t-test was used, andthe detection result is expressed as a ratio (%), and P is expressed as a ratio (%)<0.05 is a significant difference, there isStatistical significance.
2 results
Subject subjective evaluation after 28d, subjects were subjected to subjective evaluation, and the content included improvement in 4 aspects of clear, level, mottle, and acne marks, as detailed in table 3.
Table 7 subjective evaluation of subject (n)
In the whole research process of product safety evaluation, the subjects do not have adverse reactions, and the traditional Chinese medicine composition stock solution is proved to have higher safety.
Conclusion 3
Tyrosinase is a key enzyme in the melanin production process, and is the most important molecular target for researching melanin. The melanin inhibitor is synthesized by melanocytes only, so that the melanin inhibitor designed by taking tyrosinase as a target point has no obvious toxic or side effect on human bodies, and the early-stage melanin inhibition strategy is also mostly concentrated on tyrosinase. The melanin inhibitor has remarkable whitening effect, so that the melanin inhibitor becomes the first choice of the most basic components in cosmetics.
The results of this test showed that 87.5% of subjects considered improved skin clarity, 82.5% of subjects considered more even skin, 72.5% of subjects considered less mottle, and 65% of subjects considered effective in reducing acne marks, based on subjective evaluation of the subjects after 28d use. In the experimental process, 40 subjects have no adverse reaction, and the whitening and freckle-fading formula stock solution is proved to be capable of effectively inhibiting melanin from generating, homogenizing facial complexion, obviously improving color spots, acne marks and the like, enabling skin to be even and clear and high in use safety.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (8)
1. The traditional Chinese medicine composition for whitening skin and removing freckles is characterized by being prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract or bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of dwarf lilyturf tuber extract, 2-4 parts of licorice root extract, and 2-4 parts of camellia extract or rose extract.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of ophiopogon root extract, 2-4 parts of licorice root extract and 2-4 parts of camellia extract.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of dittany bark extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of ophiopogon root extract, 2-4 parts of licorice root extract and 2-4 parts of rose extract.
4. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of ophiopogon root extract, 2-4 parts of licorice root extract and 2-4 parts of camellia extract.
5. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
8-10 parts of ginseng extract, 8-10 parts of bletilla striata extract, 6-8 parts of chamomile extract, 4-6 parts of lucid ganoderma extract, 4-6 parts of pseudo-ginseng extract, 4-6 parts of saffron extract, 4-6 parts of hairyvein agrimony extract, 4-6 parts of ophiopogon root extract, 2-4 parts of licorice root extract and 2-4 parts of rose extract.
6. The use of the traditional Chinese medicine composition according to any one of claims 1-5 in preparing cosmetics for whitening skin and removing freckles.
7. The use according to claim 6, wherein the cosmetic comprises one or more of an emulsion, a cream, an essence, a foundation.
8. The use according to claim 6, wherein the cosmetic is for cleansing, isolating or screening the skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210987357.8A CN115177695B (en) | 2022-08-17 | 2022-08-17 | Traditional Chinese medicine composition for whitening skin and removing freckles and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210987357.8A CN115177695B (en) | 2022-08-17 | 2022-08-17 | Traditional Chinese medicine composition for whitening skin and removing freckles and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115177695A CN115177695A (en) | 2022-10-14 |
| CN115177695B true CN115177695B (en) | 2024-01-02 |
Family
ID=83523971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210987357.8A Active CN115177695B (en) | 2022-08-17 | 2022-08-17 | Traditional Chinese medicine composition for whitening skin and removing freckles and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115177695B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302440A (en) * | 2011-09-23 | 2012-01-04 | 孙丽华 | Chinese medicinal herb softening, whitening, anti-aging, wrinkle-smoothing and freckle-removing cosmetic composition |
| KR20150079246A (en) * | 2013-12-31 | 2015-07-08 | 주식회사 풀무원 | A cosmetic composition effective for skin whitening comprising multiple herbal extracts |
| CN110403885A (en) * | 2018-04-26 | 2019-11-05 | 佛山市嘉懿行农业科技有限公司 | A kind of cosmetic composition and preparation method thereof containing Chinese medicine extract |
| CN110638954A (en) * | 2019-10-19 | 2020-01-03 | 云南滇药医药健康产业有限公司 | Whitening and freckle removing composition and preparation method thereof |
| CN113662890A (en) * | 2021-07-26 | 2021-11-19 | 天地慈(东莞)生物科技有限公司 | Antioxidant whitening composition and preparation method thereof |
-
2022
- 2022-08-17 CN CN202210987357.8A patent/CN115177695B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102302440A (en) * | 2011-09-23 | 2012-01-04 | 孙丽华 | Chinese medicinal herb softening, whitening, anti-aging, wrinkle-smoothing and freckle-removing cosmetic composition |
| KR20150079246A (en) * | 2013-12-31 | 2015-07-08 | 주식회사 풀무원 | A cosmetic composition effective for skin whitening comprising multiple herbal extracts |
| CN110403885A (en) * | 2018-04-26 | 2019-11-05 | 佛山市嘉懿行农业科技有限公司 | A kind of cosmetic composition and preparation method thereof containing Chinese medicine extract |
| CN110638954A (en) * | 2019-10-19 | 2020-01-03 | 云南滇药医药健康产业有限公司 | Whitening and freckle removing composition and preparation method thereof |
| CN113662890A (en) * | 2021-07-26 | 2021-11-19 | 天地慈(东莞)生物科技有限公司 | Antioxidant whitening composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王铮主编.《实用中医美容学——探寻传统源流中的美容方法》.东南大学出版社,(第1版),248-249. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115177695A (en) | 2022-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101212952B (en) | Agent for external application to the skin | |
| CN101873847B (en) | Composition for skin external application containing complex of herbal extracts | |
| CN102065836A (en) | External preparation composition for skin comprising ginseng flower or ginseng seed extracts | |
| CN101849899A (en) | Chinese medicinal compound extract and cosmetics comprising same as active ingredient | |
| CN107737272A (en) | A kind of Chinese medicine composition and its methods for making and using same with freckle removing and whitening effect | |
| CN100536825C (en) | Hair washing shampoo containing snake bile and Chinese herbal medicine | |
| CN109771351A (en) | A kind of Whitening, spot composition and its application | |
| CN105381007A (en) | Externally-applied traditional Chinese medicine composition with effect on whitening skin, preparation as well as preparation method and application thereof | |
| CN110200837A (en) | A kind of hair growth composition | |
| KR20080056369A (en) | Cosmetic compositions containing ginseng extract and deep sea water | |
| CN115177695B (en) | Traditional Chinese medicine composition for whitening skin and removing freckles and application thereof | |
| EP4297715A1 (en) | Nano- or micro-emulsion compositions and methods of use thereof | |
| CN113476321A (en) | Application of isosteviol in preparing cosmetic preparation for whitening skin and resisting melanin generation | |
| CN112516025A (en) | Plant extract composition cream with transdermal absorption effect and preparation method thereof | |
| US9161900B2 (en) | Cosmetic composition for inhibiting hair loss and enhanced hair growth | |
| CN104207972A (en) | Compositions comprising extracts of Bursera simaruba | |
| CN106619278A (en) | Traditional Chinese medicine combination extract with effects of removing beverage and whitening skin and application | |
| KR20070065925A (en) | Skin whitening cosmetics composite containing oriental herb extract and manufacturing method thereof | |
| Dodon et al. | The study of biofield energy treatment based herbomineral formulation in skin health and function | |
| CN110169932A (en) | A kind of nti-freckle compound essential oil and preparation method thereof | |
| KR20140013791A (en) | Functional cosmetic composition comprising ginsenosides rh2 and rg3 | |
| CN114533612A (en) | Composition with effects of relieving, removing red and repairing and application thereof | |
| KR20080056370A (en) | Cosmetic compositions containing ginseng and siberian ginseng extracts and deep sea water | |
| CN113440468A (en) | Skin conditioner compound for whitening and brightening skin, novel skin cream and preparation method thereof | |
| CN108888561B (en) | Whitening composition and cosmetic prepared from same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |